Therapy News and Research

RSS

Therapeutic hypothermia after resuscitation from cardiac arrest improves survival and functional status

Mayo Clinic researchers confirmed that patients who receive therapeutic hypothermia after resuscitation from cardiac arrest have favorable chances of surviving the event and recovering good functional status.

19 Feb 2011

Upsher-Smith expands voluntary recall of Jantoven Warfarin Sodium, 3 mg Tablets

Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.

19 Feb 2011

Kentucky, Virginia LapBand centers install Crospon's EndoFLIP system

Crospon, an Irish medical device developer based in Galway, has announced that its EndoFLIP system is now being used in two leading LapBand centers in Kentucky and Virginia.

19 Feb 2011

Apria Healthcare fourth quarter revenues decrease 1.6% to $527.7 million

Apria Healthcare Group Inc., a quality, cost-efficient provider of home healthcare products and services in the United States, today announced its financial results for the quarter and year ended December 31, 2010.

18 Feb 2011

Study: Low levels of Klotho protein may serve as early warning sign of CKD

Low levels of the anti-aging hormone Klotho may serve as an early warning sign of the presence of kidney disease and its deadly cardiovascular complications, according to findings by UT Southwestern Medical Center researchers.

18 Feb 2011

EGS publishes three clinical studies on TIF procedure over past four months

EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced that three clinical studies on transoral fundoplication have been published over the past four months.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Scientists establish biomarker strategy to diagnose variety of cancer types

A team of biologists, clinical oncologists, pathologists and information scientists has established a strategy for identifying biomarkers. If a particular pattern of these biomarkers can be detected in the blood, this indicates a cancerous disease. An interdisciplinary research breakthrough that opens many doors.

18 Feb 2011

CCS Atrial Fibrillation Guidelines help Canadian physicians recognize and treat heart conditions

The Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010 help Canadian physicians better recognize and treat a common heart condition that affects about 250,000 Canadians.

18 Feb 2011

Scottsdale Healthcare implants MRI-safe pacemaker

Scottsdale Healthcare Shea Medical Center is the first hospital in the southwestern United States to implant an MRI-safe pacemaker, a major technological breakthrough for patients who need MRI diagnostic scans, which can damage older style pacemakers or cause serious health complications.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

New study: Asthma may have relationship with airway microbiota composition

Asthma may have a surprising relationship with the composition of the species of bacteria that inhabit bronchial airways, a finding that could suggest new treatment or even potential cures for the common inflammatory disease, according to a new UCSF-led study.

18 Feb 2011

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.

18 Feb 2011

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

18 Feb 2011

ACS to provide therapy related assessment and training services to UCP

Ancillary Care Solutions, the nationwide leader in helping healthcare organizations establish and manage physical and occupational therapy programs, today announced it was chosen to provide therapy related assessment and training services to United Cerebral Palsy of Central Arizona, a non-profit health and human service organization that has served children and adults with disabilities since 1952.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).

17 Feb 2011

ASTRO develops radiation therapy guideline for treating bone metastases

The American Society for Radiation Oncology Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation Oncology-Biology-Physics, an official journal of ASTRO.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011